Key Points
- Glaukos Director Aimee Weisner sold 15,000 shares on Feb. 19 at an average price of $117.38 for a total of $1,760,700, reducing her stake by 44.37% to 18,806 shares (SEC filing).
- In its most recent quarter (Feb. 17), Glaukos reported EPS -$0.28 (missing estimates) while revenue came in at $143.12 million, up 35.6% year‑over‑year and above analyst expectations.
- The stock trades in a 52‑week range of $73.16–$130.69, carries a MarketBeat consensus of "Moderate Buy" with an average price target of $133.69, and is ~99.04% institutionally owned.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Aimee Weisner sold 15,000 shares of the firm's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director directly owned 18,806 shares of the company's stock, valued at $2,207,448.28. This represents a 44.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Glaukos Price Performance
Shares of Glaukos stock opened at $120.27 on Tuesday. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $130.69. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10. The stock has a market cap of $6.91 billion, a PE ratio of -36.89 and a beta of 0.70. The company's 50-day moving average price is $115.47 and its two-hundred day moving average price is $99.23.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. During the same period in the prior year, the firm earned ($0.40) EPS. The business's revenue for the quarter was up 35.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.
Wall Street Analyst Weigh In
GKOS has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a research report on Thursday, January 22nd. William Blair upgraded Glaukos to a "strong-buy" rating in a report on Friday, January 30th. JPMorgan Chase & Co. raised their target price on shares of Glaukos from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, October 30th. Truist Financial raised their price objective on shares of Glaukos from $120.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday, December 18th. Finally, Stephens lifted their price objective on shares of Glaukos from $115.00 to $145.00 and gave the stock an "overweight" rating in a research report on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and an average price target of $133.69.
Read Our Latest Analysis on Glaukos
Institutional Investors Weigh In On Glaukos
Large investors have recently bought and sold shares of the business. Riverbridge Partners LLC increased its stake in Glaukos by 41.0% in the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier's stock valued at $46,454,000 after acquiring an additional 165,673 shares during the period. Holocene Advisors LP raised its holdings in shares of Glaukos by 40.1% in the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier's stock valued at $108,030,000 after buying an additional 299,118 shares during the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of Glaukos by 4.2% in the second quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier's stock worth $2,056,000 after acquiring an additional 800 shares during the last quarter. Baird Financial Group Inc. raised its position in Glaukos by 17.7% in the 2nd quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier's stock worth $6,546,000 after purchasing an additional 9,545 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Glaukos in the 3rd quarter valued at $936,000. 99.04% of the stock is currently owned by institutional investors.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
